ValiRx Plc announced that a patent covering its lead therapeutic compound VAL201 has been granted in Australia. VAL201 has shown efficacy in prostate, breast and ovarian cancer models as well as addressing endometriosis or hormone induced abnormal cell growth in women. Based on results in endometrial models, VAL201 has been shown to reduce the abnormal endometrial growth, whilst leaving other hormone-induced activities working normally. The compound is currently progressing well through its clinical development. The original patent and technology covering VAL201 is licensed by ValiRx from Cancer Research Technology (CRT) for use in androgen resistant cancer. ValiRx has all rights to perform pre-clinical and clinical developments and obtaining regulatory approvals in all territories. ValiRx also has full, worldwide rights and control over the commercialisation and development of potential treatments.

ValiRx plc, Annual General Meeting, Apr 22, 2013.

ValiRx plc reported consolidated final results for the year ended December 31, 2012. For the year, the company's revenue was £216,269 compared with £455,226 a year ago. Operating loss was £2,348,884 compared with £1,084,456 a year ago. Loss on ordinary activities before taxation was £2,329,904 compared with £1,065,038 a year ago. Loss for the year was £2,163,948 compared with £932,685 a year ago. Loss for the year and total comprehensive income was £2,150,055 or 0.17 pence per basic and diluted share compared with £784,773 or 0.10 pence per basic and diluted share a year ago. Net cash outflow from operating activities was £2,131,745 compared with £1,460,375 a year ago. Payments to acquire intangible assets were £132,145 compared with £193,511 a year ago. Payments to acquire tangible assets were £2,579 compared with £8,831 a year ago.